Several forms of anti-cancer therapy rely on what is known as immunotherapeutic anti-cancer strategies, therapies that encourage the body's natural defenses, such as cytotoxic T lymphocytes, to aid in destroying tumors. However, immunotherapeutic methods are often not effective at removing established tumors for a number of reasons including a loss of the ability of the cytotoxic T lymphocytes to recognize the tumor and a physical barrier separating the lymphocytes and the tumor.
Now, Dr. Alan M. Kleinfeld and Clifford Okada of the Torrey Pines Institute for Molecular Studies in San Diego, CA, have added another reason to this list. They discovered that tumors secrete fatty acids which inhibit the cytotoxic T lymphocytes' ability to kill tumor cells.
"We found two things," explains Dr. Kleinfeld. "First, the most common type of free fatty acids, which at normal levels are essential for life, at high levels prevents the cytotoxic T lymphocytes from destroying tumor cells. The second thing is that human breast cancer cells, but not normal tissue from the same breast, produce very large amounts of the type of free fatty acids that block the cytotoxic T lymphocytes. Thus the cancer may have a way of defending itself against attack by the immune system, thereby reducing the potential efficacy of novel anti cancer therapies that rely on a functioning immune system."
The free fatty acids act against cytotoxic T lymphocytes by blocking a number of the lymphocytes' signaling events. For example, they keep certain proteins from being phosphorylated and they also prevent an increase in intracellular calcium that is essential for the cytotoxic T lymphocytes to kill the tumor cells. Dr. Kleinfeld suspects that these signaling events are being blocked at the cells' membranes.
These results from the Torrey Pines Institute for Molecular Studies raise the possibilities of new therapeutic targets for cancer, such as those that may transport free fatty acids out of the tumor. Alternatively, free fatty acid levels in the blood could be used to help gauge the aggressive potential of a tumor.
The American Society for Biochemistry and Molecular Biology (ASBMB) is a nonprofit scientific and educational organization with over 11,000 members in the United States and internationally. Most members teach and conduct research at colleges and universities. Others conduct research in various government laboratories, nonprofit research institutions, and industry.
Founded in 1906, the Society is based in Bethesda, Maryland, on the campus of the Federation of American Societies for Experimental Biology. The Society's primary purpose is to advance the sciences of biochemistry and molecular biology through its publications, the Journal of Biological Chemistry, the Journal of Lipid Research, Molecular and Cellular Proteomics, and Biochemistry and Molecular Biology Education, and the holding of scientific meetings.
For more information about ASBMB, see the Society's website at www.asbmb.org.
The manuscript for the Journal of Lipid Research paper can be downloaded from the following URL: